 |
| (Credit: Getty Images) |
New research explores the effects of e-cigarette use on RNA expression.
E-cigarette use, including vaping, is often seen as a safer and trendier alternative to traditional tobacco products.
However, the new study in Scientific Reports suggests an elevation of carcinogenic cellular signaling pathways in exclusive e-cigarette users when compared to non-users.
“Exosomal microRNAs play a crucial role in inflammation and disease processes like cancer,” says first author Dongmei Li, a professor of clinical and translational research at the University of Rochester Medical Center, and the director of Translational Science Statistical Support Services for the Clinical and Translational Science Institute.
“However, little is known about how exclusive e-cigarette use affects exosomal microRNAs, which regulate genes that influence cancer-causing pathways.”
By comparing exosomal microRNA profiles between exclusive e-cigarette users and non-users, the researchers identified several exosomal microRNAs that are upregulated—more active than normal—in exclusive e-cigarette users. These overactive microRNAs are involved in cancer pathways, suggesting an elevation of carcinogenic cellular signaling pathways in exclusive e-cigarette users.
“Our results contribute significantly to understanding the potential health risks of e-cigarette use and should be considered by medical professionals and the public to protect public health,” Li says.
E-cigarettes are electronic smoking devices that vaporize liquid for inhalation by the user. These liquids and aerosols typically contain various combinations of propylene glycol, vegetable glycerin, nicotine, flavoring agents, and other chemicals.
According to the National Youth Tobacco Survey, e-cigarettes are the most commonly used tobacco product among high school and middle school students.
With the National Youth Tobacco Survey of 2024 reporting that 7.8% of high school students and 3.5% of middle school students self-reported current e-cigarette use, and with e-cigarettes the most prevalent tobacco product used by those groups, exploring the potential link the behavior has with cancer is increasingly important to inform the public and future regulatory policies.
Li and Zidian Xie utilized blood plasma specimens from the Population Assessment of Tobacco and Health Study biorepositories to analyze exosomal epigenetic biomarkers—microRNAs—associated with flavored e-cigarette usage. They recorded changes in the epigenetic biomarkers and related biological pathways in the group of users, using non-users as a reference.
Li and Xie then collaborated with Irfan Rahman, professor of environmental medicine, and Sadiya Bi Shaikh to conduct experiments on primary airway epithelial cells, including wound-healing and DNA damage assays from non-users, to determine the toxicity and inflammatory response. Shaikh, a postdoctoral researcher in Rahman’s lab, conducted the wound-healing and DNA damage assays.
“The toxicity genomic marker in e-cigarette users is not known,” Rahman says. “This study was defined using transcriptomic and cell-based studies because these biomarkers may be related to precancerous development and vascular damage. Noninvasive biomarkers are identified here that would help develop diagnostics for e-cigarette use causing toxicity.”
“Our study results will spark further investigations into the impact of exclusive e-cigarette use on plasma exosomal miRNAs and other biomarkers related to cancer risks, which will help us better understand the toxicity of e-cigarette use,” Li says.
Support for this research came from the National Institute of Environmental Health Sciences of the National Institutes of Health, the Western New York–based Center for Research on Flavored Tobacco Products under cooperative agreement U54CA228110 from the National Cancer Institute of the National Institutes of Health and the US Food and Drug Administration, and the National Institute on Aging.
This work was also partly supported by the University of Rochester’s Clinical and Translational Science Award (CTSA) number UL1 TR002001 from the National Center for Advancing Translational Sciences of the National Institutes of Health.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Source: University of Rochester
Original Study DOI: 10.1038/s41598-025-85373-9
Important Notice: This article was originally published at www.futurity.org by U. Rochester-URMC where all credits are due.
Disclaimer
The watching, interacting, and participation of any kind with anything on this page does not constitute or initiate a doctor-patient relationship with Veripeudic.com. None of the statements here have been evaluated by the Food and Drug Administration (FDA). The products of Veripeudic.com are not intended to diagnose, treat, cure, or prevent any disease. The information being provided should only be considered for education and entertainment purposes only. If you feel that anything you see or hear may be of value to you on this page or on any other medium of any kind associated with, showing, or quoting anything relating to Veripeudic.com in any way at any time, you are encouraged to and agree to consult with a licensed healthcare professional in your area to discuss it. If you feel that you’re having a healthcare emergency, seek medical attention immediately. The views expressed here are simply either the views and opinions of Veripeudic.com or others appearing and are protected under the first amendment.
Veripeudic.com promotes evidence-based natural approaches to health, which means integrating her individual scientific and clinical expertise with the best available external clinical evidence from systematic research. By individual clinical expertise, I refer to the proficiency and judgment that individual clinicians acquire through clinical experience and clinical practice.
Veripeudic.com does not make any representation or warranties with respect to the accuracy, applicability, fitness, or completeness of any multimedia content provided. Veripeudic.com does not warrant the performance, effectiveness, or applicability of any sites listed, linked, or referenced to, in, or by any multimedia content.
To be clear, the multimedia content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen in any website, video, image, or media of any kind. Veripeudic.com hereby disclaims any and all liability to any party for any direct, indirect, implied, punitive, special, incidental, or other consequential damages arising directly or indirectly from any use of the content, which is provided as is, and without warranties.
